Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib) was named Best New Drug at the Scrip Awards 2025, held by Citeline. The Best New Drug Award recognizes excellence in pharmaceutical development and the drug that represents the best therapeutic advance in its area.

GlobeNewsWire • Dec 12, 2025

Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting Transcript

Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting Transcript

Seeking Alpha • Dec 8, 2025

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute leukemia pts –

GlobeNewsWire • Dec 8, 2025

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on December 1, 2025, the Company granted inducement awards to purchase up to 15,500 shares of common stock to one new employee under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

GlobeNewsWire • Dec 3, 2025

Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025, at 11:15 a.m. ET.

GlobeNewsWire • Dec 1, 2025

Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth

Syndax Pharmaceuticals (SNDX) posted strong Q3 results, driven by robust Revuforj and Niktimvo sales, despite a slight revenue miss. SNDX's commercial ramp is accelerating, with Revuforj prescriptions up 25% and management confident cash reserves will fund operations to profitability. 2026 revenue projections for SNDX range from $245M to $512M, depending on growth scenarios, but risks include reimbursement and competitive shifts.

Seeking Alpha • Nov 30, 2025

Syndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Healthcare Conference 2025 Transcript

Syndax Pharmaceuticals, Inc. ( SNDX ) UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM EST Company Participants Michael Metzger - CEO & Director Nicholas Botwood - Head of Research & Development and Chief Medical Officer Steven Closter - Chief Commercial Officer Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division Okay. Well, thanks for joining.

Seeking Alpha • Nov 10, 2025

Syndax Pharmaceuticals: Thesis Firing On All Cylinders, Sales Acceleration In 2026

Syndax Pharmaceuticals, Inc. remains a Buy, with Revuforj and Niktimvo launches accelerating and a strong clinical and commercial trajectory into 2026. Revuforj's recent NPM1 AML approval expands its addressable market, reinforcing first-mover advantage and supporting $1B+ peak sales potential. Niktimvo's robust uptake and Incyte partnership will aid the march to profitability, while also providing significant downside cushion.

Seeking Alpha • Nov 5, 2025

Syndax Pharmaceuticals, Inc. (SNDX) Q3 2025 Earnings Call Transcript

Syndax Pharmaceuticals, Inc. ( SNDX ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Sharon Klahre - Vice President of Investor Relations & Communications Michael Metzger - CEO & Director Steven Closter - Chief Commercial Officer Nicholas Botwood - Head of Research & Development and Chief Medical Officer Keith Goldan - CFO, Treasurer & Chief Accounting Officer Conference Call Participants Priyanka Grover - JPMorgan Chase & Co, Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Bradley Canino - Guggenheim Securities, LLC, Research Division Yuxi Dong - Jefferies LLC, Research Division Peter Lawson - Barclays Bank PLC, Research Division Ellen Horste - TD Cowen, Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Justin Zelin - BTIG, LLC, Research Division Salim Syed - Mizuho Securities USA LLC, Research Division Xiaochuan Dai - UBS Investment Bank, Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Jason Zemansky - BofA Securities, Research Division Presentation Operator Good day, everyone, and welcome to the Syndax Third Quarter 2025 Earnings Conference Call.

Seeking Alpha • Nov 4, 2025

Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update

– $45.9 million in total revenue, representing 21% growth over 2Q25 –  – $32.0 million Revuforj ® (revumenib) net revenue; total Revuforj prescriptions in 3Q25 increased 25% over 2Q25, highlighting strong demand – – $45.8 million Niktimvo™ (axatilimab-csfr) net revenue reported by Incyte; $13.9 million in collaboration revenue reported by Syndax – – Revuforj FDA-approved in R/R NPM1m AML on October 24, 2025 – – $456.1 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today reported its financial results for the third quarter ended September 30, 2025, and provided a business update.

GlobeNewsWire • Nov 3, 2025